Lymphoid Malignancies Clinical Trial
Official title:
A Phase 1, Multi-Center, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies
The purpose of this study is to determine if HGS1029 is safe and well tolerated in patients with relapsed or refractory lymphoid malignancies.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00383994 -
Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation
|
Phase 1 | |
Recruiting |
NCT04329728 -
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Terminated |
NCT01998035 -
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT01705847 -
A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies
|
Phase 1 | |
Completed |
NCT00406809 -
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Terminated |
NCT02739360 -
Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820
|
Phase 4 | |
Terminated |
NCT00992732 -
Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders
|
Phase 2 | |
Active, not recruiting |
NCT02452697 -
Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT
|
Phase 2 | |
Not yet recruiting |
NCT06047886 -
CD34 Selection Using the Automated CliniMACS Prodigy
|
Phase 1 | |
Completed |
NCT02181478 -
Intra-Osseous Co-Transplant of UCB and hMSC
|
Early Phase 1 | |
Terminated |
NCT01596127 -
Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System
|
Phase 1/Phase 2 | |
Completed |
NCT00820508 -
Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies
|
Phase 1 | |
Recruiting |
NCT05371054 -
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00529438 -
RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies
|
Phase 1 | |
Completed |
NCT01435447 -
Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies
|
Phase 2 | |
Completed |
NCT00508807 -
RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies
|
Phase 1 | |
Completed |
NCT02091063 -
ACY-1215 for Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 |